You are here

Final decisions amending, or not amending, the current Poisons Standard, April 2018

Scheduling medicines and poisons

10 April 2018

Book pagination

1.3 Stenabolic (SR9009)

Part A - Final decisions on matters referred to an expert advisory committee (November 2017)

1. Advisory Committee on Medicines Scheduling (ACMS #22)

1.3 Stenabolic (SR9009)

Delegate's final decision
Final decision:

The delegate's final decision is to include stenabolic and other synthetic REV-ERB agonists in Schedule 4 with an Appendix D (Part 5) entry as follows:

Schedule 4 - New Entry

# STENABOLIC (SR9009) and other synthetic REV-ERB agonists.

Appendix D, Part 5 - New Entry

STENABOLIC (SR9009) and other synthetic REV-ERB agonists.

Index - New Entry

STENABOLIC (SR9009) and other synthetic REV-ERB agonists
cross reference: SR9011, GSK2945, GSK0999, GSK5072, GSK2667

Schedule 4
Appendix D, Part 5

Implementation date: 1 June 2018
Reasons:

As no new evidence has been received to alter the interim decision for stenabolic and other synthetic REV-ERB agonists, the delegate has confirmed that the final decision and reasons for the final decision are identical to the interim decision.

Public submissions on the interim decision

No public submissions were received.

Interim decision

The interim decision for Stenabolic (SR9009) was published on the TGA website on 5 February 2018 at Scheduling delegates' interim decisions and invitation for further comment: ACCS/ACMS, November 2017 - 1.3. Stenabolic (SR9009).

Scheduling proposal

The pre-meeting scheduling proposal for cardarine was published on the TGA website on 6 September 2017 at Consultation: Proposed amendments to the Poisons Standard - ACCS, ACMS and Joint ACCS/ACMS meetings, November 2017.

Book pagination